drugset
drugset / Trial / NCT03222310

A Study to Evaluate the Effect of a Potent Cytochrome P450 (CYP) 3A Inhibitor on Ipatasertib

NCT03222310 ↗

Phase 1 Completed 15 enrolled Hoffmann-La Roche
NaSingle-groupOpen-labelTreatment

Summary

This study will be a single center, open-label, 2-period, fixed-sequence, Phase 1 drug-drug interaction study in healthy subjects. The primary purpose of this study is to evaluate the effect of itraconazole on the PK of ipatasertib and its primary metabolite (G-037720).

Timeline

Start
2017-07-18
Primary completion
2017-09-06
Completion
2017-09-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Ipatasertib Small molecule 100 mg Oral
Subject Itraconazole Small molecule 100 mg Oral

Indications

No indication recorded.